Skip to main content
SpringerLink
Log in

Orale Faktor-Xa-Inhibitoren oder Warfarin zur Schlaganfallprophylaxe

ROCKET-AF- und ARISTOTLE-Studie

Oral factor Xa inhibitors or warfarin for stroke prophylaxis

ROCKET AF and ARISTOTLE studies

  • Klinische Studien
  • Published:
Der Internist Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY (2011) Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‚real world‘ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 107:584–589

    Article  PubMed  Google Scholar 

  2. Buller H, Deitchman D, Prins M, Segers A (2008) Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 6:1313–1318

    Google Scholar 

  3. Buller HR, Lensing AW, Prins MH et al (2008) Dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 112:2242–2247

    Article  PubMed  CAS  Google Scholar 

  4. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151

    Google Scholar 

  5. Garcia D, Libby E, Crowther MA (2010) The new oral anticoagulants. Blood 115:15–20

    Article  PubMed  CAS  Google Scholar 

  6. Hylek EM, D’Antonio J, Evans-Molina C et al (2006) Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 37:1075–1080

    Article  PubMed  Google Scholar 

  7. Meinertz T, Nitschmann S (2011) Warfarin oder Dabigatran bei Patienten mit Vorhofflimmern. RE-LY-Studie („Randomized Evaluation of Long-term anticoagulation therapY“). Internist 52:462–465

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt für sich und seinen Koautor an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Sigmund-Freud-Str. 25, 53105, Bonn, Deutschland

    C. Hammerstingl &  G. Nickenig

  2. Am Börn 7, 59457, Werl-Westönnen, Deutschland

    S. Nitschmann

Authors
  1. C. Hammerstingl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Nickenig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Nitschmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to G. Nickenig or S. Nitschmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hammerstingl, C., Nickenig, G. & Nitschmann, S. Orale Faktor-Xa-Inhibitoren oder Warfarin zur Schlaganfallprophylaxe. Internist 53, 893–896 (2012). https://doi.org/10.1007/s00108-012-3106-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-012-3106-6

Search

Navigation